Cenobamate - Open Access .click

Results 61 to 70 of about 1,087 (181)

Exploration of the mechanism of action of cenobamate

Seizure: European Journal of Epilepsy
Antiseizure medications have varied effects on neurotransmitter receptors and ion channels in the brain, yet how these mechanisms of action (MoAs) translate to clinical efficacy is not well understood. Cenobamate, a tetrazole alkyl carbamate antiseizure medication (ASM), has a dual MoA: preferential inhibition of the persistent sodium current (INaP ...
Raman, Sankar, Louis, Ferrari, Marc, Kamin +2 more
openaire +2 more sources

Intraoperative electrocorticography guiding surgical resection in epilepsia partialis continua secondary to cardiac myxoma embolism: A clinical vignette

Epileptic Disorders, EarlyView.
Olalla Urdanibia‐Centelles +7 more
wiley +1 more source

Beyond seizure control: Non–seizure‐related outcomes in focal‐onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study

Epilepsia, EarlyView.
Abstract Objective Cenobamate is approved for treatment of focal seizures in adults, but evidence on non‐seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal‐onsEt SeizureS (BLESS) study evaluated patient‐ and clinician‐reported outcomes for up to 52 weeks of cenobamate treatment.
Simona Lattanzi +206 more
wiley +1 more source

Do preclinical seizure models predict success or failure in anti‐seizure drug development? A retrospective analysis of 89 compounds with divergent clinical outcomes for epilepsy

Epilepsia, EarlyView.
Abstract Anti‐seizure medication (ASM) discovery remains a major challenge despite over 30 commercially available options. One persistent obstacle for any promising candidate compound to successfully move from preclinical study to clinical approval has been the ambiguity in preclinical model selection.
Wolfgang Löscher, Melissa Barker‐Haliski +1 more
wiley +1 more source

Table2_Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database.XLS

Objective:This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023.Methods:Data related to cenobamate-associated ADEs from the third quarter
Huiqin Xu (1459831) +3 more
core +1 more source

Seizure improvement following intravenous immunoglobulin in drug‐resistant mesial temporal lobe epilepsy associated with systemic lupus erythematosus

Epileptic Disorders, EarlyView.
Kristijonas Puteikis +3 more
wiley +1 more source

Treatment patterns, strategies, and preferences after first anti‐seizure medication failure in focal epilepsy: Findings from the SANAD and SANAD II trial cohorts and a survey of UK epilepsy specialists

Epilepsia, EarlyView.
Abstract Objective To describe treatment decisions after first anti‐seizure medication (ASM) failure in focal epilepsy and describe how they have changed across two trial eras, and whether observed prescribing matched clinicians stated preferences. Methods We analyzed the focal epilepsy cohorts from two UK pragmatic, randomized trials, Standard and New
Isaac J. Egesa +4 more
wiley +1 more source

Persistence of electroclinical findings in an adult patient with SETD1B‐related epilepsy

Epileptic Disorders, EarlyView.
Rohan Shankar, Abdulrahman Bukhari, Irfan S. Sheikh +2 more
wiley +1 more source

Reduction in emergency room visits with cenobamate in pharmaco-resistant epilepsy: an observational study

Brain Disorders
Objective: Cenobamate (Xcopri) is an antiepileptic drug introduced in Israel in July 2023 that has shown promise in reducing seizure frequency in patients with focal seizures.This study aims to evaluate the real-world effectiveness and safety of ...
Gal Khazin +4 more
doaj +1 more source

Resective epilepsy surgery in an adult with ARID1B‐related disorder and focal cortical dysplasia type IIb

Epileptic Disorders, EarlyView.
Émile Moura Coelho da Silva +5 more
wiley +1 more source

epilepsy
anticonvulsants
humans

tetrazoles
carbamates
chlorophenols

seizures
adult
treatment outcome